144 related articles for article (PubMed ID: 12040964)
1. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects.
Arisawa H; Fukui K; Imai E; Fujise N; Masunaga H
Arzneimittelforschung; 2002; 52(4):225-32. PubMed ID: 12040964
[TBL] [Abstract][Full Text] [Related]
2. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle.
Arisawa H; Fukui K; Fujise N; Masunaga H
Arzneimittelforschung; 2002; 52(2):81-8. PubMed ID: 11878203
[TBL] [Abstract][Full Text] [Related]
3. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: effects on respiratory and cardiovascular systems.
Arisawa H; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(3):162-7. PubMed ID: 11963642
[TBL] [Abstract][Full Text] [Related]
4. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
[TBL] [Abstract][Full Text] [Related]
5. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
Omori Y; Asari T; Maruyama K; Kusama H; Kojima M; Shibata N
Arzneimittelforschung; 2003; 53(5):342-50. PubMed ID: 12854361
[TBL] [Abstract][Full Text] [Related]
6. (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors.
Iga Y; Arisawa H; Ogane N; Saito Y; Tomizuka T; Nakagawa-Yagi Y; Masunaga H; Yasuda H; Miyata N
Jpn J Pharmacol; 1998 Nov; 78(3):373-80. PubMed ID: 9869272
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs.
Washio T; Kohsaka K; Arisawa H; Masunaga H
Arzneimittelforschung; 2003; 53(1):26-33. PubMed ID: 12608011
[TBL] [Abstract][Full Text] [Related]
8. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
[TBL] [Abstract][Full Text] [Related]
9. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
10. General pharmacological properties of the main metabolite of flosequinan.
Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
[TBL] [Abstract][Full Text] [Related]
11. General pharmacology of recombinant human basic fibroblast growth factor.
Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
[TBL] [Abstract][Full Text] [Related]
12. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
[TBL] [Abstract][Full Text] [Related]
13. Salivary secretion and histopathological effects after single administration of the muscarinic agonist SNI-2011 in MRL/lpr mice.
Iwabuchi Y; Katagiri M; Masuhara T
Arch Int Pharmacodyn Ther; 1994; 328(3):315-25. PubMed ID: 7542865
[TBL] [Abstract][Full Text] [Related]
14. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
Murata T; Murai T; Kanai T; Ogaki Y; Sanai K; Kanda H; Sato S; Kajikawa N; Umetsu T; Matsuura H
Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
[TBL] [Abstract][Full Text] [Related]
15. General pharmacological properties of the new vasodilator flosequinan.
Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
[TBL] [Abstract][Full Text] [Related]
16. Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs.
Masunaga H; Ogawa H; Uematsu Y; Tomizuka T; Yasuda H; Takeshita Y
Eur J Pharmacol; 1997 Nov; 339(1):1-9. PubMed ID: 9450610
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of radiolabelled SNI-2011, a novel muscarinic receptor agonist, in healthy volunteers. Comprehensive understanding of absorption, metabolism and excretion using radiolabelled SNI-2011.
Washio T; Kohsaka K; Arisawa H; Masunaga H; Nagatsuka S; Satoh Y
Arzneimittelforschung; 2003; 53(2):80-6. PubMed ID: 12642962
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study.
Leung KC; McMillan AS; Wong MC; Leung WK; Mok MY; Lau CS
Clin Rheumatol; 2008 Apr; 27(4):429-36. PubMed ID: 17899308
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
[TBL] [Abstract][Full Text] [Related]
20. Effect of cevimeline on salivary components in patients with Sjögren syndrome.
Suzuki K; Matsumoto M; Nakashima M; Takada K; Nakanishi T; Okada M; Ohsuzu F
Pharmacology; 2005 May; 74(2):100-5. PubMed ID: 15722648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]